VK-2735 is under clinical development by Viking Therapeutics and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VK-2735’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VK-2735 overview

VK-2735 is under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). They act by targeting the incretin hormones-glucagon like peptide1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide/Gastric inhibitory polypeptide receptor (GIP-R). It is administered through subcutaneous route and oral route in the form of tablet.

Viking Therapeutics overview

Viking Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. Its pipeline products include VK2809, VK2735, VK0612, VK0214, VK5211 and others. The company’s product VK0214 treats orphan indication, a rare X-linked inherited neurological disorder; VK2809 treats orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease and VK0612 an inhibitor of fructose -1,6-biphosphatase for type 2 diabetes. Viking Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of VK-2735’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.